Additional Proxy Soliciting Materials (definitive) (defa14a)
31 Oktober 2022 - 10:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
☐ |
Preliminary Proxy Statement |
☐ |
Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2)) |
☐ |
Definitive Proxy Statement |
☒ |
Definitive Additional Materials |
☐ |
Soliciting Material under §240.14a-12 |
ACORDA THERAPEUTICS, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
☐ |
Fee paid previously with preliminary materials. |
☐ |
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules
14a-6(i)(1) and 0-11 |
Special Meeting November 4.
We need your vote.
Please ensure your voice is heard by voting today.
Dear Acorda stockholder:
The special meeting of Acorda
stockholders is this Friday, November 4, 2022. The time to vote is NOW! Please vote your shares today!
Support
Acordas Business Plan
Your Board of Directors, ISS and Glass Lewis, all recommend that you vote FOR the Reverse Stock
Split (proposal 2). Approval of the Reverse Stock Split proposal is key to Acordas ability to execute its business plan.
Acorda issued a
press release on October 27, 2022 on its long-term business plan and financial guidance through 2027, which we encourage you to review prior to your vote at the special meeting.
Acorda has developed a long-term business plan to increase the value of the Company, focused on growing
INBRIJA® (levodopa inhalation powder), maximizing AMPYRA® (dalfampridine), and implementing additional operational and manufacturing
efficiencies. Acorda has substantial liquidity which the Company expects will allow it to execute on this business plan.
Your vote is critically
important. Please vote today. Vote FOR approval of the Reverse Split proposal to support execution of Acordas long-term business plan.
Internet voting and voting by the QR code you received are the quickest ways to vote. Otherwise please contact D.F. King for assistance voting your shares at 1-800-967-5051 or via email at ACOR@dfking.com.
How Shareholders Can Vote:
You are encouraged to cast
your vote promptly FOR the Reverse Stock Split proposal without further delay.
Online: www.proxyvote.com Please have the control number that was sent to
you in the mail.
By QR Code: Please vote using the QR code you received by email
or on the voting instruction form.
By phone: Call 1-800-967-5051, Mondaythis Thursday 9am10pm ET only.
Mail: Sign, date, and
return your proxy card in the postage-paid, stamped envelope provided, but make sure your vote is delivered by Thursday of this week.
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
Von Jan 2024 bis Jan 2025